TITLE

Dissociation between antiresorptive effects at endosteal surfaces vs bone-forming effects on cortical (periosteal) surfaces

AUTHOR(S)
Recker, Robert R
PUB. DATE
September 2012
SOURCE
IBMS BoneKEy;Sep2012, Vol. 9 Issue 9, p164
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
The article discusses the development of antiresorptive agents for the treatment of patients with osteoporosis. It mentions that bisphosphonates (BPs) was the first class drug developed to treat patients with postmenopausal osteoporosis. It offers information on cathepsin K (CatK), and odanacatib (ODN). It notes that ODN was developed to correct the imbalance between bone resorption and formation.
ACCESSION #
100370770

 

Related Articles

  • Diffuse skeletal pain after administration of alendronate. Ozaras, Nihal; Rezvani, Aylin // Indian Journal of Pharmacology;Aug2010, Vol. 42 Issue 4, p245 

    Background: Osteoporosis is caused by bone resorption in excess of bone formation, and bisphosphonates, are used to inhibit bone resorption. Alendronate, a biphosphonate, is effective for both the treatment and prevention of osteoporosis in postmenopausal women. Side effects are relatively few...

  • OSTEOPOROSIS: HOW AND HOW LONG TO TREAT. Pfeifer, Marija // Problemy Endokrinologii;2017 Supplement, p17 

    Osteoporosis is the most prevalent bone disease and a major health-economic problem worldwide. It is defi ned as a systemic skeletal disease characterized by low bone mass and micro-architectural deterioration of bone tissue with a consequent increase in bone fragility and susceptibility to...

  • IDENTIFICATION OF A POTENT INHIBITOR AGAINST CATHEPSIN-K FOR OSTEOPOROSIS: A STRUCTURE BASED VIRTUAL SCREENING APPROACH. MADHU SUDHANA SADDALA; A. USHA RANI // International Journal of Pharma & Bio Sciences;Jan-Mar2013, Vol. 4 Issue 1, pB-927 

    Cathepsin K (Cat K) is a lysosomal cysteine protease which involves in degradation of bone may lead to severe bone fragility in Osteoporosis patients. Cat K is the primary enzyme involved in osteoclastic bone resorption. Inhibition of Cat K represents a potential drug target for Osteoporosis....

  • The therapeutic use of bisphosphonates. Compston, Juliet E. // BMJ: British Medical Journal (International Edition);9/17/94, Vol. 309 Issue 6956, p711 

    Investigates the therapeutic uses of bisphosphonates. Inhibition of the substance of bone mineralization; Variation in the antiresorptive potency of different compounds of bisphosphonates; Effects of bisphosphonates on bone resorption.

  • EFFECTS OF ALENDRONATE ON PARTICLE-INDUCED OSTEOLYSIS IN A RAT MODEL. Millett, Peter J.; Allen, Matthew J.; Bostrom, Mathias P.G. // Journal of Bone & Joint Surgery, American Volume;Feb2002, Vol. 84-A Issue 2, p236 

    Background: Particle-induced osteolysis is currently a major problem affecting the long-term survivorship of total joint replacements. Alendronate is a third-generation bisphosphonate that blocks osteoclastic bone resorption. The objective of this study was to determine whether alendronate...

  • Bisphosphonates: Slowing osteoporosis progression. Waxman, Jack // Cortlandt Forum;Nov2007, Vol. 20 Issue 11, p24 

    The article focuses on the implication of biphosphonates in slowing the progression of osteoporosis. They can decrease the fracture risk by 50 percent due to their positive antiresorptive effects. Prolonged binding at hydroxyapatite sites in the mineral bone matrix allow inhibition of...

  • Bisphosphonates effective in treatment of osteoporosis. Zablocki, Elaine // Managed Healthcare Executive;May2009, Vol. 19 Issue 5, p20 

    The article discusses the benefits of bisphosphonates for the treatment of osteoporosis. It states that bisphosphonates is a group of medicines that decreases bone resorption by binding sites of bone remodelling and inhibiting the cells that break down bony tissue. This group includes Fosamax,...

  • Response to Teriparatide in a patient with bisphosphonate-induced atypical femur fracture. Shetty, Sahana; Kapoor, Nitin; Thomas, Nihal; Paul, Thomas V // IBMS BoneKEy;Aug2014, Vol. 11 Issue 8, p559 

    Bisphosphonates are the first-line and commonly prescribed drugs for the treatment of osteoporosis. They act by decreasing bone resorption, hence altering bone remodeling, which may lead to a low bone turnover state. Atypical femur fracture is one of the rare complications seen following...

  • CORR Insights: Are Race and Sex Assessment Associated With the Occurrence of Atypical Femoral Fractures? Lane, Joseph // Clinical Orthopaedics & Related Research;Mar2014, Vol. 472 Issue 3, p1028 

    The article discusses the association of race and sex with the occurrence of atypical femoral fractures. Topics discussed include the use of biphosphonates for osteoporosis treatment, benefits of biphosphonates as they decrease bone resorption and bone formation and declined use of osteoporotic...

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics